Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrop
Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrop
CAMBRIDGE, Mass.
Scientists discover potential disease-fighting 'warheads' in bacteria
Scientists discover potential disease-fighting 'warheads' in bacteria
Washington.
Gene silencing alleviates Machado-Joseph disease in study with mice
Gene silencing alleviates Machado-Joseph disease in study with mice
June 20 (UPI) -- A gene-silencing technique was effective at slowing the progression of ataxia, a loss of muscle control and coordination of the upper and lower extremities, according to a st...
Repurposing promising cancer drugs may lead to a new approach to treating TB
Repurposing promising cancer drugs may lead to a new approach to treating TB
Promising experimental cancer chemotherapy drugs may help knock out another life-threatening disease.
Caffeine from four cups of coffee protects the heart with the help of mitochondria
Caffeine from four cups of coffee protects the heart with the help of mitochondria
Caffeine consumption has been associated with lower risks for multiple diseases, including type II diabetes, heart disease, and stroke, but the mechanism underlying these protective effects has been u...
Merck KGaA partners with Alibaba Health in China
Merck KGaA partners with Alibaba Health in China
Merck KGaA (MRK.
Geron posts positive data
Geron posts positive data
GERON provided updated findings from the phase 2/3 IMerge trial, which is assessing single-agent imetelstat in patients with transfusion-dependent myelodysplastic syndromes.
Novo's pioneering diabetes pill beats Victoza, Januvia in tests
Novo's pioneering diabetes pill beats Victoza, Januvia in tests
COPENHAGEN (Reuters) - Novo Nordisk’s experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co’s Januvia and its own best-s...
This Speedy Genetic Tool Might Soon Let Scientists Create New Genes 'Overnight'
This Speedy Genetic Tool Might Soon Let Scientists Create New Genes 'Overnight'
Two graduate students developed a method for synthesizing DNA that could make it much faster, cheaper and easier for biologists to create synthetic DNA sequences.
Novo, Kallyope link to develop obesity, diabetes therapies
Novo, Kallyope link to develop obesity, diabetes therapies
Novo Nordisk and Kallyope are joining forces to discover novel peptide therapeutics for obesity and diabetes.
FDA declines to approve Valeant's plaque psoriasis lotion
FDA declines to approve Valeant's plaque psoriasis lotion
(Reuters) - Valeant Pharmaceuticals International Inc’s plaque psoriasis treatment did not get approval from U.
Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
ZURICH/LONDON (Reuters) - Swiss drugmaker Roche (ROG.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand